Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell

Liver International

Volumn 27, Issue 2, 2007, Pages 201-208

  Yow, C M N ^a   Wong, C K ^b   Huang, Z ^c   Ho, R J ^d  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ALA; Apoptosis; HepG2; p53; Photodynamic therapy; PpIX

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; AMINOLEVULINIC ACID; PROTEIN P53; PROTOPORPHYRIN; PHOTOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL ASSAY; CELL MEMBRANE; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG CYTOTOXICITY; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIGHT INTENSITY; LIVER CELL CARCINOMA; MICROSCOPY; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; SPECTROMETRY; UPREGULATION; CELL SURVIVAL; DRUG COMBINATION; LIVER TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE;

AMINOLEVULINIC ACID; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG THERAPY, COMBINATION; HUMANS; LIVER NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247610932     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01412.x     Document Type: Article

References (26)

1. Hall AJ, Wild CP. Liver cancer in low and middle income countries. Br Med J 2003; 326: 994-5.
2. World Health Organisation. The World Health Report. World Health Organisation, Switzerland, 2004; 122-123.
3. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005; 4: 283-93.
4. van Duijnhovenfh, Rovers JP, Englemann K, et al. Photodynamic therapy with 5,10,15,20-tetrakis(m-hydroxyphenyl) bacteriochlorin for colorectal liver metastases is safe and feasible: Results from a phase I study. Ann Surg Oncol 2005; 12: 808-16.
5. Huang Z. Photodynamic therapy in China: 25 years of unique history. Part two -clinical experiences. Photodiag Photodyn Ther 2006; 3: 71-84.
6. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B:BIol 1992; 14: 275-92.
7. Lwasa F, Sassa S, Kappas A. δ-Aminolaevulinate synthase in human HepG2 hepatoma cells. Repression by haemin and induction by chemicals. Biochem J 1989; 262: 807-13.
8. Vonarx-Coinsman V, Foultier MT, de Brito LX, et al. HepG2 human hepatocarcinoma cells: An experimental model for photosensitization by endogenous porphyrins. J Photochem Photobiol B 1995; 3: 201-8.
9. Otake M, Nishiwaki M, Kobayashi Y, et al. Selective accumulation of ALA-induced PpIX and photodynamic effect in chemically induced hepatocellular carcinoma. Bri J Cancer 2003; 89: 730-6.
10. Castano AP, Nemidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part two -cellular signaling, cell metabolism and modes of cell death. Photodiag Photodyn Ther 2004; 2: 1-23.
11. Terada T, Nakanuma Y. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Pathol Int 1996; 46: 764-70.
12. Mise K, Tashiro S, Yogita S, et al. Assessment of the biological malignancy of hepatocellular carcinoma: Relationship to clinicopathological factors and prognosis. Clin Cancer Res 1998; 4: 1475-82.
13. Nakano A, Watanabe N, Nishizaki Y, et al. Immunohistochemical studies on the expression of P-glycoprotein and p53 in relation to histological differentiation and cell proliferation in hepatocellular carcinoma. Hepatol Res 2003; 25: 158-65.
14. Chao JC, Chu CC. Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World J Gastroenterol 2004; 10: 37-41.
15. Fisher AM, Ferrario A, Rucker N, et al. Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function. Cancer Res 1999; 59: 331-5.
16. Tong Z, Singh G, Rainbow AJ. The role of the p53 tumor suppressor in the response of human cells to photofrin-mediated photodynamic therapy. Photochem Photobiol 2000; 71: 201-10.
17. Yow CMN, Chen JY, Mam NK, et al. Cellular uptake, subcellular, localization and photodamaging effect of temoporfin (mTHPC) in nasopharyngeal carcinoma cells: Comparison with hematoporphyrin derivative (HPD). Cancer Lett 2000; 157: 123-31.
18. Cubeddu R, Canti G, Taroni P, Valentini G. Study of porphyrin fluorescence in tissue samples of tumour-bearing mice. J Photochem Photobiol B 1997; 29: 171-8.
19. Date M, Fukuchi K, Namiki Y, et al. Therapeutic effect of photodynamic therapy using PAD-S31 and diode laser on human liver cancer cells. Liver Intern 2004; 24: 142-8.
20. Luo Y, Kessel D. Initiation of apoptosis versus necrosis by photodynamic therapy with chloroaluminum phthalocyanine. Photochem Photobiol 1997; 66: 479-83.
21. Webber J, Luo Y, Crilly R, et al. An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo. J Photochem Photobiol B 1996; 735: 209-11.
22. McKay BC, Ljungman M, Rainbow AJ. Potential roles fro p53 in nucleotide excision repair. Carcinogenesis 1999; 20: 1389-96.
23. Zhimin T, Gurmit S, Andrew JR. The role of the p53 tumor suppressor in the response of human cells to photofrin-mediated photodynamic therapy. Photochem Photobiol 2000; 71: 201-10.
24. Schuler M, Bossy-Wetzel E, Goldstein JC, et al. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 2000; 275: 7337-42.
25. Ding HF, Fisher DE. p53, caspase 8, and regulation of apoptosis after ionizing radiation. J Pediatr Hematol Oncol 2001; 23: 185-8.
26. Nasrin M, Clark P. Impaired p53 expression, function, and nuclear localization in calreticulin-deficient cells. Mol Biol Cell 2004; 15: 1862-70.